Academia and industry collaboration could mean myriad healthcare innovations
Agilent Technologies Inc. announced recently it has formed a strategic scientific collaboration with the University of Southern California (USC) Michelson Center for Convergent Bioscience to create an Agilent Center of Excellence (CoE) in Biomolecular Characterization.
The center will be housed in Michelson Hall, which opened last year at USC. The aim of the center is to establish a convergence of researchers across science and engineering to work together on multidisciplinary approaches for the development of improved health care through new drugs, diagnostics, and medical devices.
“Agilent’s collaboration with the Michelson Center is an excellent example of how academia and industry can work together, sharing knowledge and expertise to shorten the timeline between scientific discoveries and real-world applications,” said Darlene Solomon, senior vice president and chief technology officer for Agilent. “Convergent bioscience research requires successful collaboration across multiple disciplines – a holistic approach that is central to Agilent’s view of the future.”
Key to the Agilent CoE will be a collaboration with renowned USC Michelson Center for Convergent Bioscience principal investigator Dr. Valery Fokin. Research at the Fokin lab at USC focuses on chemical reactivity and biological interactions at the molecular level. The lab will contribute to multiple collaborative drug discovery projects ranging from chemical synthesis of screening and focused libraries and biological assay implementation to the development of targeted drug delivery systems, diagnostics, and vaccines.
SOURCE: USC College of Letters, Arts and Sciences